NEW YORK, NY--(Marketwired - Jul 25, 2013) - Nuvilex, Inc. (
Last week Nuvilex moved one step closer to going head to head with Eli Lilly when it completed a blockbuster acquisition. The deal strengthened the company's hand dramatically, and now Nuvilex owns exclusive worldwide licenses associated with the live-cell encapsulation-based pancreatic cancer treatment that it will use to go head to head with Eli Lilly. Additionally, these licenses include worldwide rights to utilize the live-cell encapsulation platform technology to develop treatments for any and all cancer types, regardless of the cell type encapsulated.
About $25-million have been invested in two Phase II clinical trials in patients with advanced, inoperable pancreatic cancer using the combination of the widely used anti-cancer drug, ifosfamide, together with encapsulated cells capable of converting the ifosfamide into its "cancer-killing" form and in pre-clinical studies of other applications for the technology. In addition, Nuvilex has put almost another $2-million into furthering the development of the cell encapsulation technology itself.
This investment for the Silver Spring, Maryland-based biotech was made for just this challenge. Gemzar, the standard single drug for pancreatic cancer patients equates to about $1.4-billion annually to Eli Lilly. There is a lot at stake in the future Phase III clinical trials -- for Eli Lilly, for Nuvilex and for cancer patients who are looking for a better treatment than the current single agent "gold standard."
One has to imagine with the data already on the table that this is a head to head matchup that Nuvilex greatly anticipates while Eli Lilly might dread the end results.
Continue reading this article at www.stockmarketmediagroup.com/features.
About Stock Market Media Group
Stock Market Media Group is a full service Investment Relations firm specializing in Research and Content Development. It offers a platform for CEOs to tell their story through the media with Research Reports, CEO Interviews and Feature Articles while building a library of Research for Investors. For more information: www.stockmarketmediagroup.com
Contact Information:
Contact:
Stock Market Media Group
(646) 397-4020